DailyIQ
|
Sector:HealthcareAll sectors
Last updated 3 minutes ago

LLY·Eli Lilly and Company

$.
+. (+.%)
After Hours
High
$1,166.29
Open
$1,142.97
Market Cap
1065.51B
52W High
$1,166.29
Low
$1,111.00
P. Close
$1,132.53
P/E
42.15
52W Low
$623.78
Fwd P/E
25.43
DailyIQ Est.
$1401.03
Technical Score (1D)
91
BUY
News Sentiment
86
BULLISH
Novo Nordisk’s recent endorsement of Veru’s experimental obesity therapy signals that Lilly sees a strategic fit with its own obesity portfolio, potentially opening new revenue streams if collaboration terms are favorable. The partnership could accelerate Lilly’s obesity pipeline, and investors will look to the next earnings release for guidance on the financial scope and any regulatory milestones that could unlock commercial upside. Traders should watch the earnings call for details on the collaboration’s structure and timing, as these factors will shape short‑term expectations. Meanwhile, post‑hoc analyses from the ATTAIN‑1 and ATTAIN‑2 trials show Foundayo produced significant weight loss in women across all menopause stages, with the highest dose yielding up to 30.4 lbs in perimenopausal participants and 28.2 lbs in post‑menopausal women. These results suggest a broader indication for Foundayo, potentially expanding its market to menopausal women and strengthening Lilly’s competitive positioning against other GLP‑1 agents. The weight‑loss data also hint at cardiometabolic benefits, which could improve Lilly’s overall obesity portfolio appeal to clinicians and payers. The convergence of the Veru partnership and Foundayo’s expanded indication may position Lilly as a more comprehensive obesity solution provider in the near term. Traders should monitor regulatory announcements regarding Veru’s platform and any FDA decisions on Foundayo’s expanded labeling, as these could materially affect the company’s outlook. In addition, watch for updates on Lilly’s collaboration terms with Novo Nordisk, as a favorable deal could drive short‑term upside in the next 1–10 trading days.
Earnings Summary
Eli Lilly and Company is a global pharmaceutical firm specializing in the discovery, development, and commercialization of human medicines, with a core focus on diabetes, oncology, and immunological disorders. Operating in the highly competitive drug manufacturers sector, Lilly leverages a broad therapeutic portfolio that includes GLP‑1 obesity drugs such as Mounjaro and Trulicity, oncology agents like Verzenio, and emerging gene‑therapy collaborations, positioning it at the forefront of medical innovation. In the most recent two quarters, Lilly posted EPS of $7.54 in Q4 2025 and $8.55 in Q1 2026, both surpassing analyst expectations of $6.74 and $6.79 respectively, while revenue climbed to $19.292 billion and $19.799 billion, up from $17.601 billion and $15.558 billion in Q3 2025 and Q2 2025. This represents a clear acceleration in both earnings and top‑line growth, with the company beating estimates in five of the last six quarters, only missing in Q1 2025. The upward trajectory is further underscored by a 28.3 % average weight‑loss efficacy reported for retatrutide, reinforcing the momentum behind Lilly’s GLP‑1 leadership. Year‑over‑year, revenue has grown consistently each quarter, and EPS has trended upward, reflecting robust pricing power and cost discipline. The pattern of frequent beats against consensus, coupled with sustained revenue expansion, signals a resilient business model even as the company navigates a highly competitive obesity market. Recent developments include a $4 billion acquisition of three vaccine and infectious‑disease firms, new RNA‑based partnerships, and a strategic pivot to diversify beyond obesity drugs. The company also cut its planned German investment by 50 % to reallocate capital to a U.S. site, potentially delaying European launches of Mounjaro and Zepbound. Phase 3 data for retatrutide showed significant weight‑loss and metabolic benefits, bolstering Lilly’s weight‑loss leadership and raising valuation sustainability concerns. Investors should watch for the integration progress of the vaccine acquisitions, the timing of regulatory approvals for retatrutide and other GLP‑1 candidates, and the impact of the German investment cut on European market share. Additionally, monitoring the adoption of LillyDirect’s digital health ecosystem and any updates to the company’s guidance will be key to assessing whether the current earnings momentum can be sustained.

EPS

EstBeatMiss
$2.52$4.30$6.08$7.85$9.63Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$8.81 - -
Q1'26$6.79$8.55+25.9%
Q4'25$6.74$7.54+11.9%
Q3'25$5.89$7.02+19.2%
Q2'25$5.59$6.31+12.9%
Q1'25$3.54$3.34-5.7%

Revenue

EstBeatMiss
$11.6B$14.1B$16.6B$19.2B$21.7BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$20.5B - -
Q1'26$17.8B$19.8B+11.1%
Q4'25$18.1B$19.3B+6.4%
Q3'25 - $17.6B -
Q2'25 - $15.6B -
Q1'25 - $12.7B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

LLY Stock Snapshot

LLY is currently trading at $1123.00, giving Eli Lilly and Company a market cap of 1065.51B and a P/E ratio of 42.1. Today's range spans $1111.00–$1166.29, with shares opening at $1142.97 and moving down $9.53 (0.8%) from the prior close. DailyIQ's technical score sits at 91/100 (BUY) with a news sentiment reading of 86/100.

Over the past year LLY has traded between $623.78 and $1166.29 - the current price is +80.0% off the 52-week low and -3.7% from the high. 40 analysts cover the stock with a Buy consensus and a mean 12-month target of $1215.10 (range $850.00–$1500.00), implying upside of +8.2%.

Eli Lilly and Company (LLY) has earned its mega-cap status in Healthcare - and the current data backs it up. Technical score 91/100 (BUY), sentiment 86/100 (bullish), price $1123.00 (near 52-week highs). (P/E: 42.1) The 52-week window from $623.78 to $1166.29 establishes the range, and the current bullish reading says this stock isn't testing support - it's testing what the next leg of the trend looks like.

For portfolio managers constructing Healthcare exposure, a mega-cap with a BUY signal and bullish news backdrop represents the kind of conviction-generating setup that justifies moving from benchmark weight to overweight. The 91/100 technical score at $1123.00 (near 52-week highs) provides the entry discipline; the 1065.51B market cap provides the exit liquidity — a combination most position-sizing frameworks actively seek.